Internal Medicine, Rheumatology · Little Rock, AR
NPI
1437141322
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
6 Shackleford Dr
Little Rock, AR, 72211
Phone (501) 500-5001
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
100,463 services
Medicare patients, 2024
1,117
Average age 72
Drug cost, 2024
$7.4M
11,034 prescriptions
Company payments, 2025
$4,461
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jasen C CHI was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 22,000 times for 16 patients. In total Jasen C CHI billed 100,463 services in 69 codes, and Medicare paid $1.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-05-22.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 22,000 | 16 | $3.66 | $80K |
| J3262 Injection, tocilizumab, 1 mg | Office | 19,621 | 14 | $4.66 | $91K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 17,820 | 46 | $9.30 | $166K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 7,050 | 28 | $33.60 | $237K |
| Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 5,130 | 48 | $23.74 | $122K |
| J0897 Injection, denosumab, 1 mg | Office | 4,380 | 73 | $19.10 | $84K |
| Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 2,750 | 16 | $25.83 | $71K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 2,030 | 26 | $24.84 | $50K |
| J9312 Injection, rituximab, 10 mg | Office | 1,660 | 15 | $61.57 | $102K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,476 | 38 | $0.20 | $300 |
| Q5121 Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | Office | 1,260 | 21 | $17.84 | $22K |
| 86235 Immunoassay | Office | 679 | 97 | $17.48 | $12K |
| 99213 Office E&M - Established | Office | 676 | 570 | $50.22 | $34K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 654 | 80 | $0.70 | $461 |
| 73620 X-ray - Lower Extremity | Office | 493 | 268 | $17.18 | $8,472 |
By year: 2022 $2.0M for 135,177 services; 2023 $1.6M for 116,240 services; 2024 $1.3M for 100,463 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86235 Immunoassay | 679 | 97 | $17.48 | $12K |
| 83516 Immunoassay | 122 | 61 | $11.30 | $1,379 |
| 86225 Immunoassay | 98 | 98 | $13.40 | $1,313 |
| 86226 Immunoassay | 98 | 98 | $11.81 | $1,157 |
| 86200 Immunoassay | 66 | 66 | $12.69 | $838 |
| 86431 Immunoassay | 65 | 65 | $5.56 | $361 |
| 82306 Clinical Chemistry | 19 | 19 | $29.01 | $551 |
Medicare prescription drug claims, 2024
In 2024, the drug Jasen C CHI prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,962 prescriptions and refills. In total Jasen C CHI wrote 11,034 Medicare prescriptions that cost $7.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,962 | 3,067 | 697 | $59K |
| Prednisone Generic | 893 | 1,161 | 337 | $5,512 |
| Colchicine Generic | 841 | 1,092 | 340 | $55K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 757 | 757 | 233 | $17K |
| Sulfasalazine Generic | 624 | 893 | 215 | $7,687 |
| Methotrexate Methotrexate Sodium | 556 | 850 | 192 | $9,460 |
| Gabapentin Generic | 544 | 867 | 199 | $7,402 |
| Tramadol Hcl Generic | 404 | 406 | 161 | $2,294 |
| Leflunomide Generic | 329 | 532 | 126 | $16K |
| Diclofenac Sodium Generic | 256 | 367 | 97 | $5,805 |
| Pregabalin Generic | 251 | 282 | 87 | $6,113 |
| Azathioprine Generic | 229 | 340 | 87 | $8,065 |
| Sulindac Generic | 215 | 319 | 78 | $2,345 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 213 | 213 | 31 | $3,614 |
| Enbrel Sureclick Etanercept | 205 | 209 | 44 | $1.5M |
Brand drugs: 1,969 claims; generic drugs: 9,052 claims; opioid claims: 1,658.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jasen C CHI $4,461 ($4,461 in general payments such as food, travel and fees) from 16 companies. The largest payer was Abbvie Inc. with $1,188.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.